In addendum to my previous post showcasing my interest in Lagos Business School (LBS); I was able to deduce that Lagos Business School (LBS) convey a passion for its program as well as a high level of self and situational awareness for her students and this lead me to the greater journey based on my experience by applying for Lagos Business School Executive MBA Cohort 28 last year 2022 in order to the year started in January 2023.
Lo and behold by first case study review tends towards a module in Analysis Business Problems discussing: “The Future of Bio Pasteur”.
BioPasteur is an innovative Biotech company with two owners Thompson and Jeff. BioPasteur engaged the service of PSL and Co that I represent as Senior Consulting to proffer recommendation why they should introduce a new drug that can solve type 1 and type 2 diabetic called DIASTOP. Hence, we recommend and proffer impact for the risk either to be accepted or mitigated.
BioPasteur will be gain a lot of market share for ages 45years – 70 years respectively with a great margin of 80% impact bottom line on the Organization profit margin. Withdrawal of DIASTOP not delivery of the expectation of the drug as campaigned and known by patience on what the experiment had offer could cause a reputation damage and lack of vote of confidence for the organization. However, not improving on the quality with stress testing with human not relying on Non-human alone may in future create a bad reputation damage after earning interest over time.
BioPasteur ideal value proposition with our recommendation will be to deploy DIASTOP to the market based on expectations and profit margin impact towards the organization while mitigating the defects on ensuring Phase two of the DIASTOP will be provided in nearest future and ensure FDA is aware of such enhancement in order for their license not to be revoked by FDA.
BioPasteur to engage patience users through a feedback mechanism such as survey or questionnaire towards areas of complains on defect per complications if any.
BioPasteur to invest in more research and consider the risk associated with the drugs which 1% of severe cases due to the food and drug exchange FDA can recall the drugs but different mechanism can be adopted.
BioPasteur should recognized that 1% of all cases which is 0.3% 3 out of 1,000 people are tested are not sufficient enough for the next phase with human, despite the approval giving by FDA.
BioPasteur can progress further in biotech investment due to their disruptive innovations of drugs doing well in 2009 at 10% and the case of how long they will do in terms of investment in another 4 years versus the 4 years of early start because they could not produce more in which they require the right technology they ought it utilized in order not to lose credibility and it will be vote of no confidence.
The essence of business should be managed with risk mitigated in order for FDA that approved not to recall for good organization reputation and not have negative impact with through drug research on side effects.
My journey into Lagos Business School and Experience Series 3 will continue on my next blogpost please stay tune…….Adeshina Lawal EMBA28
YOUR JOURNEY TO SPIRITUAL AND EMOTIONAL MATURITY